PRACTICES FOR CYTOMEGALOVIRUS DIAGNOSIS, PROPHYLAXIS AND TREATMENT INALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS - A REPORT FROM THE WORKING PARTY FOR INFECTIOUS-DISEASES OF THE EBMT
P. Ljungman et al., PRACTICES FOR CYTOMEGALOVIRUS DIAGNOSIS, PROPHYLAXIS AND TREATMENT INALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS - A REPORT FROM THE WORKING PARTY FOR INFECTIOUS-DISEASES OF THE EBMT, Bone marrow transplantation, 12(4), 1993, pp. 399-403
During the past few years major progress has been made in the diagnosi
s and therapy of CMV infection after allogeneic BMT. The aim of this s
urvey was to investigate the use of diagnostic techniques, use of prop
hylaxis and the therapeutic strategies among members of the EBMT. Seve
nty centers from 20 countries responded to the survey. Sixty-seven cen
ters (96%) routinely tried to diagnose CMV from the blood. Fifty-seven
centers used standard or rapid isolation techniques. Thirty-seven cen
ters used one of the newly developed techniques, antigenemia detection
in leukocytes or PCR together with isolation, while 10 centers used o
ne of these two techniques without standard isolation. Fifty-five cent
ers regularly performed bronchoscopy and bronchoalveolar lavage on the
suspicion of CMV pneumonia but only 12 centers required detection of
CMV in specimens from the lavage or lungs as the indication to start t
herapy, 31 centers started therapy on symptoms of pneumonia combined w
ith CMV detection from any site. Prophylaxis was used in 54 centers (8
4%). The most commonly used regimen was high-dose acyclovir which was
used by 42 centers, while seven centers used ganciclovir. The strategy
of early therapy was used by 53 centers (76%) and was most frequently
based on detection of viremia or CMV antigen in the blood. CMV pneumo
nia was treated by a combination of ganciclovir and iv immunoglobulin
by 64 centers, by foscarnet and immunoglobulin in 5 centers and by gan
ciclovir alone in 5 centers. CMV gastrointestinal disease was treated
by antiviral therapy alone in 18 centers and by a combination of antiv
iral therapy and iv immunoglobulin in 46 centers. We conclude that the
new approaches to CMV diagnosis and therapy are widely used in Europe
; major differences exist in the diagnostic criteria for CMV disease a
nd in the criteria for initiating therapy.